Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA3 | P07451 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA6 | P23280 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442310 | 0.98 | TSHR (0.44) | TSHRHPGDLMNAALDH1A1PDE3B | |
| SCHEMBL18920642 | 0.94 | TSHR (0.45) | TSHRHPGDLMNAALDH1A1PDE3B | |
| SCHEMBL4811573 | 0.87 | TSHR (0.41) | TSHRHPGDLMNAALDH1A1PDE3B | |
| SCHEMBL1639509 | 0.85 | CA12 (0.38) | TSHRHPGDLMNAALDH1A1PDE3B | |
| SCHEMBL17242958 | 0.83 | CYP4F2 (0.44) | TSHRALDH1A1CA1CA2CA12 | |
| SCHEMBL12118230 | 0.82 | PAOX (0.38) | ALDH1A1 | |
| SCHEMBL12287701 | 0.82 | PAOX (0.38) | ALDH1A1 | |
| SCHEMBL14683456 | 0.81 | TBXAS1 (0.39) | LMNA | |
| SCHEMBL1888744 | 0.80 | TBXAS1 (0.50) | TSHRLMNAALDH1A1 | |
| SCHEMBL8465150 | 0.80 | TBXAS1 (0.36) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056433-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-03-04 | — | — | US | disclosed |
| US-20100056433-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-03-04 | — | — | US | disclosed |
| US-20100022446-A1 | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
| US-20100022446-A1 | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
| US-20100016238-A1 | Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| WO-2009141392-A1 | PROCESS | NOVO NORDISK A/S (DK) | 2009-11-26 | — | — | WO | disclosed |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2009-08-13 | — | — | US | disclosed |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2009-08-13 | — | — | US | disclosed |
| WO-2008087186-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087188-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087189-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087187-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087190-A2 | USE OF PEPTIDES IN COMBINATION WITH SURGICAL INTERVENTION FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007009894-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016238-A1 | Peptides for Use in the Treatment of Obesity | MC4R, GIPR, MC3R | TSHR 148/4885HPGD 2890/4885LMNA 3996/4885 |
| US-20100022446-A1 | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity | MC4R, GIPR, MC3R | TSHR 142/4885HPGD 2698/4885LMNA 4278/4885 |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | MC4R, MC3R, GIPR | TSHR 145/4885HPGD 3105/4885LMNA 4302/4885 |
| US-20100056433-A1 | Novel Peptides for Use in the Treatment of Obesity | MC4R, MC3R, GIPR | TSHR 145/4885HPGD 3105/4885LMNA 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.